EFPIA and EBE Welcome NOR-SWITCH Results as a Valuable Step Forward
EFPIA and EBE welcome the results of the NOR-SWITCH study on biosimilar switching* and acknowledge its preliminary results as a step in the right direction of robust data generation that continues to enhance physician and patient confidence in using biosimilars.
EFPIA and EBE also welcome the effort of the Norwegian authorities and investigators to initiate and carry out the NOR-SWITCH study.
